Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, US collaborating with international researchers, have developed a sophisticated AI algorithm that performs advanced computational analysis to identify potential therapeutic targets for glioblastoma multiforme (GBM) and other cancers. Their research is described in the Feb. 2 issue of the journal…
Category: Industry News
Evobrutinib: Initiation of new patients paused in the US
News from Merck
Effects of median nerve stimulation on Tourette syndrome
Results of UK-wide double-blind sham-controlled clinical trial of the Neupulse device for suppressing tics in Tourette syndrome The trial was run by the University of Nottingham, conducted between 18th March 2022 and 5th of March 2023, sponsored by Nottingham University Hospitals NHS Trust. The aim was to evaluate the effectiveness of the Neupulse device in…
Rozanolixizumab BLA for the treatment of generalised myasthenia gravis filed with US FDA and designated for priority review
UCB, a global biopharmaceutical company, announced on 6th January 2023 that the US Food and Drug Administration (FDA) has accepted the company’s filing to review a Biologic License Application (BLA) for its investigational treatment rozanolixizumab, and that the Agency has granted Priority Review.1 Rozanolixizumab is a subcutaneous (SC) monoclonal antibody targeting the neonatal Fc receptor…
Upstaza™ gene therapy granted marketing authorisation for AADC deficiency by MHRA
PTC Therapeutics, Inc. announced on 17th November that Upstaza™ (eladocagene exuparvovec) was granted authorisation by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Upstaza is the first and only approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency and the first marketed gene therapy directly infused into the brain. It is approved for patients 18…
Upstaza™ – First disease-modifying treatment for AADC deficiency
PTC Therapeutics to launch first gene therapy directly administered into the brain PTC Therapeutics, Inc. announced on July 20th, 2022 that Upstaza™ (eladocagene exuparvovec) was granted marketing authorisation by the European Commission. Upstaza is the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency and the first marketed gene therapy directly infused into…
Aubagio study: no disease activity after 2 years
More than half (58% )of the people with multiple sclerosis (MS) treated with Aubagio (teriflunomide) showed no evidence of disease activity after two years on treatment, according to an Italian study. The study, “Evolution of teriflunomide use in multiple sclerosis: A real-world experience,” was published in the Journal of the Neurological Sciences. Aubagio is an oral disease-modifying therapy that has been…
Novel Early Intervention Study for Stroke Patients
MindMaze and The University of Auckland partner on novel early intervention study for stroke patients, expanding global breadth of research supporting the company’s brain tech solutions MindMaze, (digital therapeutics (DTx) for neurological recovery and care), in partnership with The University of Auckland, has announced a new interventional study that will aim to show the merits…
Trial failure for Jazz Pharmaceuticals’ cannabis-derived drug in MS
Jazz Pharmaceuticals nabiximols oromucosal spray did not meet the primary endpoint in a phase 3 trial, failing in its aim of improving Lower Limb Muscle Tone-6 (LLMT-6) between baseline and Day 21, as measured by the Modified Ashworth Scale (MAS). The spray is formulated from extracts of the cannabis sativa plant and contains tetrahydrocannabinol (THC) and…
